Description for medicine or protocol of treatment in detail:
|
Drug ingredients: The prescription is composed of vinegar northern bupleurum, raw white peony, fried citrus aurantium bran, mother-of-pearl, fried jujube kernel, fried atractylodes, dandelion, salvia and other drugs. Treatment regimen: Experimental group: four inverse powder plus or minus square granules (high dose) Control group: four inverse powder plus and minus square granules (low dose); Both groups were taken with warm boiled water, 2 sachets each time, 2 times/day (morning and evening) for 8 weeks.
|
Inclusion criteria
|
1. Meet the DSM-V diagnostic criteria for generalized anxiety disorder prior to enrollment;
2. Conform to the traditional Chinese medicine syndrome differentiation of liver qi stagnation transforming into fire;
3. Age between 18 and 70 years old (inclusive of both limits), gender unrestricted;
4. HAMA score ≥ 14 and ≤ 29, with anxiety mood (item 1) scoring ≥ 2 and depressive mood (item 6) scoring ≤ 2;
5. The baseline HAMA score before enrollment shows a reduction rate of < 25% compared to the screening time.6. Voluntarily participating in this clinical trial, capable of cooperating with the researchers in conducting the trial, and signing the informed consent form.
|
Exclusion criteria:
|
1. Concomitant psychiatric disorder with any of the following: delusional disorder, separation anxiety disorder, panic disorder, agoraphobia, anxiety disorder due to other somatic disorders, substance/medication-induced anxiety disorder, social anxiety disorder (social phobia), obsessive-compulsive disorder, post-traumatic stress disorder and adjustment disorder, depression, bipolar and psychotic disorder, anorexia nervosa;
2. Combination of any substance-related and addictive disorders, including alcohol, caffeine, marijuana, hallucinogens, inhalers, opioids, sedatives, hypnotic drugs, stimulants, tobacco, etc.;
3. Systemic psychotherapy has been received in the past or cannot be stopped during the trial;
4. Patients with severe or unstable heart, liver, kidney, endocrine, digestive, blood and other physical diseases;
5. Abnormal liver and kidney function: ALT or AST ≥ 1.5 times the upper limit of normal, or SCr > upper limit of normal;
6. HAMD- 17 score≥17 points;
7. Those who have suicidal tendencies as judged by the researcher;
8. Those who are unsupervised or unable to take medicine according to the doctor's instructions;
9. Known or suspected of having a history of allergy or serious adverse reactions to the test drug and its excipients, or allergic constitution;
10. Pregnant, lactating women or those who have recently planned to give birth;
11. Those who have participated in other drug clinical trials within 3 months before screening;
12. Other conditions that the investigator deems inappropriate to participate in this experiment;
|